Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 23;21(1):562.
doi: 10.1186/s13063-020-04253-x.

Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy ('START-Study'): study protocol of a randomized controlled trial

Affiliations

Efficacy of a short-term residential smoking cessation therapy versus standard outpatient group therapy ('START-Study'): study protocol of a randomized controlled trial

Jonas Dickreuter et al. Trials. .

Abstract

Background: In Germany, evidence-based outpatient smoking cessation therapies are widely available. Long-term abstinence rates, however, are limited. Studies suggest that short-term residential therapy enables a higher level of environmental control, more intense contact and greater support among patients and from therapists, which could result in higher abstinence rates. The aim of the current START-study is to investigate the long-term efficacy of a short-term residential therapy exclusively for smoking cessation, conducted by a mobile team of expert therapists.

Methods: A randomized controlled trial (RCT) is conducted to examine the efficacy of residential behavior therapeutic smoking cessation therapy compared to standard outpatient behavior therapeutic smoking cessation group therapy. Adult smokers consuming 10 or more cigarettes per day, who are willing to stop smoking, are randomized in a ratio of 1:1 between therapy groups. The primary endpoint is sustained abstinence for 6-month and 12-month periods. Secondary endpoints include smoking status after therapy, 7-day point abstinence after the 6-month and 12-month follow-ups, level of physical dependence, cost-effectiveness, use of nicotine replacement products, health-related quality of life, self-efficacy expectation for tobacco abstinence, motivational and volitional determinants of behavior change, self-reported depressive symptom severity, adverse events and possible side effects. Assessments will take place at baseline, post-therapy, and at 6-month and 12-month intervals after smoking cessation.

Discussion: There is a high demand for long-term effective smoking cessation therapies. This study represents the first prospective RCT to examine the long-term efficacy of a residential smoking cessation therapy program compared to standard outpatient group therapy as an active control condition. The residential therapeutic concept may serve as a new model to substantially enhance future cessation therapies and improve the understanding of therapeutic impact factors on tobacco abstinence. Utilizing a mobile team, the model could be applied efficiently to medical centers that do not have permanent and trained personnel for smoking cessation at their disposal.

Trial registration: German Register for Clinical Trials (Deutsches Register für Klinische Studien), DRKS00013466. Retrospectively registered on 1 April 2019. https://www.drks.de/drks_web/navigate.do?navigationId=start.

Keywords: Behavioral therapy; Inpatient; Motivational interviewing; Outpatient group therapy; Prevention; Randomized controlled trial; Residential; Smoking cessation.

PubMed Disclaimer

Conflict of interest statement

Funding sources: JL has received research funding from German Cancer Aid and the German M. Crohn/Colitis Association. AJ has received research funding from German Cancer Aid, the German Ministry of Labor, Health and Social System, Family, Women, and Senior Citizens of the State of Baden-Württemberg, as well as Johnson & Johnson.

Employment/membership: JL has received research funding and speakers’ fees from Pfizer Inc. AJ received counselling fees from Pfizer Inc. and Johnson & Johnson, financial support for talks and workshops from Sanofi, Daiichi Sankyo, Bristol-Myers Squibb, Chiesi and Medical Tribune, as well as from medical training institutes and Education Centres (Volkshochschulen). AJ is member of the AWMF-treatment guideline committee for tobacco dependence.

Figures

Fig. 1
Fig. 1
Flow chart of inclusion and study procedure
Fig. 2
Fig. 2
SPIRIT schedule of enrollment, interventions, and assessments. Abbreviations. t-1 enrollment, t0 baseline-assessment, Al./Iv. allocation/intervention, t1 post-assessment after completion of therapy, t2 6-month follow-up-assessment, t3 12-month follow-up-assessment, FTND Fagerström Test for Nicotine Dependence, SER Selbstwirksamkeits-Skala zur Raucherentwöhnung (engl. self-efficacy scale for smoking abstinence), HAPA Health Action Process Approach, EQ-5D-5L EuroQol 5-dimensions questionnaire for the assessment of health-related quality of life [, , –60]

Similar articles

Cited by

References

    1. Stanaway JD, Afshin A, Gakidou E, Lim SS. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1923–1994. - PMC - PubMed
    1. Mons U, Gredner T, Behrens G, Stock C, Brenner H. Cancers due to smoking and high alcohol consumption. Dtsch Aerzteblatt Int. 2018;115:571–577. - PMC - PubMed
    1. Kamal R, Srivastava AK, Kesavachandran CN. Meta-analysis approach to study the prevalence of chronic obstructive pulmonary disease among current, former and non-smokers. Toxicol Rep. 2015;2:1064–1074. - PMC - PubMed
    1. GBD 2015 Risk Factors Collaborators Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1659–1724. - PMC - PubMed
    1. Hackshaw A, Morris JK, Boniface S, Tang J-L, Milenković D. Low cigarette consumption and risk of coronary heart disease and stroke: meta-analysis of 141 cohort studies in 55 study reports. BMJ. 2018;360:j5855. - PMC - PubMed

Publication types

MeSH terms